Declining stroke and vascular event recurrence rates in secondary prevention trials over the past 50 years and consequences for current trial design

Keun Sik Hong, Sharon Yegiaian, Meng Lee, Juneyoung Lee, Jeffrey L. Saver

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Background: It is widely supposed, but not well-demonstrated, that cumulative advances in standard care have reduced recurrent stroke and cardiovascular events in secondary prevention trials. Methods and results: Systematic search identified all randomized, controlled trials of medical secondary stroke prevention therapies published from 1960 to 2009. Randomized, controlled trials narrowly focused on single stroke mechanisms, including atrial fibrillation, cervical carotid stenosis, and intracranial stenosis, were excluded. From control arms of individual trials, we extracted data for baseline characteristics and annual event rates for recurrent stroke, fatal stroke, and major vascular events and analyzed trends over time. Fifty-nine randomized controlled trials were identified, enrolling 66 157 patients in control arms. Over the 5 decade periods, annual event rates declined, per decade, for recurrent stroke by 0.996% (P=0.001), fatal stroke by 0.282% (P=0.003), and major vascular events by 1.331% (P=0.001). Multiple regression analyses identified increasing antithrombotic use and lower blood pressures as major contributors to the decline in recurrent stroke. For recurrent stroke, annual rates fell from 8.71% in trials launched in the 1960s to 6.10% in the 1970s, 5.41% in the 1980s, 4.04% in the 1990s, and 4.98% in the 2000s. The sample size required for a trial to have adequate power to detect a 20% reduction in recurrent stroke increased 2.2-fold during this period. Conclusions: Recurrent stroke and vascular event rates have declined substantially over the last 5 decades, with improved blood pressure control and more frequent use of antiplatelet therapy as the leading causes. Considerably larger sample sizes are now needed to demonstrate incremental improvements in medical secondary prevention.

Original languageEnglish
Pages (from-to)2111-2119
Number of pages9
JournalCirculation
Volume123
Issue number19
DOIs
Publication statusPublished - 2011 May 17

Fingerprint

Secondary Prevention
Blood Vessels
Stroke
Recurrence
Randomized Controlled Trials
Sample Size
Blood Pressure
Carotid Stenosis
Atrial Fibrillation
Pathologic Constriction
Myocardial Infarction
Regression Analysis
Therapeutics

Keywords

  • randomized controlled trial
  • recurrent stroke
  • secondary stroke prevention
  • systematic review
  • vascular event rate

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Declining stroke and vascular event recurrence rates in secondary prevention trials over the past 50 years and consequences for current trial design. / Hong, Keun Sik; Yegiaian, Sharon; Lee, Meng; Lee, Juneyoung; Saver, Jeffrey L.

In: Circulation, Vol. 123, No. 19, 17.05.2011, p. 2111-2119.

Research output: Contribution to journalArticle

@article{ef00abe4a04840e89b45551b34e17bb4,
title = "Declining stroke and vascular event recurrence rates in secondary prevention trials over the past 50 years and consequences for current trial design",
abstract = "Background: It is widely supposed, but not well-demonstrated, that cumulative advances in standard care have reduced recurrent stroke and cardiovascular events in secondary prevention trials. Methods and results: Systematic search identified all randomized, controlled trials of medical secondary stroke prevention therapies published from 1960 to 2009. Randomized, controlled trials narrowly focused on single stroke mechanisms, including atrial fibrillation, cervical carotid stenosis, and intracranial stenosis, were excluded. From control arms of individual trials, we extracted data for baseline characteristics and annual event rates for recurrent stroke, fatal stroke, and major vascular events and analyzed trends over time. Fifty-nine randomized controlled trials were identified, enrolling 66 157 patients in control arms. Over the 5 decade periods, annual event rates declined, per decade, for recurrent stroke by 0.996{\%} (P=0.001), fatal stroke by 0.282{\%} (P=0.003), and major vascular events by 1.331{\%} (P=0.001). Multiple regression analyses identified increasing antithrombotic use and lower blood pressures as major contributors to the decline in recurrent stroke. For recurrent stroke, annual rates fell from 8.71{\%} in trials launched in the 1960s to 6.10{\%} in the 1970s, 5.41{\%} in the 1980s, 4.04{\%} in the 1990s, and 4.98{\%} in the 2000s. The sample size required for a trial to have adequate power to detect a 20{\%} reduction in recurrent stroke increased 2.2-fold during this period. Conclusions: Recurrent stroke and vascular event rates have declined substantially over the last 5 decades, with improved blood pressure control and more frequent use of antiplatelet therapy as the leading causes. Considerably larger sample sizes are now needed to demonstrate incremental improvements in medical secondary prevention.",
keywords = "randomized controlled trial, recurrent stroke, secondary stroke prevention, systematic review, vascular event rate",
author = "Hong, {Keun Sik} and Sharon Yegiaian and Meng Lee and Juneyoung Lee and Saver, {Jeffrey L.}",
year = "2011",
month = "5",
day = "17",
doi = "10.1161/CIRCULATIONAHA.109.934786",
language = "English",
volume = "123",
pages = "2111--2119",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "19",

}

TY - JOUR

T1 - Declining stroke and vascular event recurrence rates in secondary prevention trials over the past 50 years and consequences for current trial design

AU - Hong, Keun Sik

AU - Yegiaian, Sharon

AU - Lee, Meng

AU - Lee, Juneyoung

AU - Saver, Jeffrey L.

PY - 2011/5/17

Y1 - 2011/5/17

N2 - Background: It is widely supposed, but not well-demonstrated, that cumulative advances in standard care have reduced recurrent stroke and cardiovascular events in secondary prevention trials. Methods and results: Systematic search identified all randomized, controlled trials of medical secondary stroke prevention therapies published from 1960 to 2009. Randomized, controlled trials narrowly focused on single stroke mechanisms, including atrial fibrillation, cervical carotid stenosis, and intracranial stenosis, were excluded. From control arms of individual trials, we extracted data for baseline characteristics and annual event rates for recurrent stroke, fatal stroke, and major vascular events and analyzed trends over time. Fifty-nine randomized controlled trials were identified, enrolling 66 157 patients in control arms. Over the 5 decade periods, annual event rates declined, per decade, for recurrent stroke by 0.996% (P=0.001), fatal stroke by 0.282% (P=0.003), and major vascular events by 1.331% (P=0.001). Multiple regression analyses identified increasing antithrombotic use and lower blood pressures as major contributors to the decline in recurrent stroke. For recurrent stroke, annual rates fell from 8.71% in trials launched in the 1960s to 6.10% in the 1970s, 5.41% in the 1980s, 4.04% in the 1990s, and 4.98% in the 2000s. The sample size required for a trial to have adequate power to detect a 20% reduction in recurrent stroke increased 2.2-fold during this period. Conclusions: Recurrent stroke and vascular event rates have declined substantially over the last 5 decades, with improved blood pressure control and more frequent use of antiplatelet therapy as the leading causes. Considerably larger sample sizes are now needed to demonstrate incremental improvements in medical secondary prevention.

AB - Background: It is widely supposed, but not well-demonstrated, that cumulative advances in standard care have reduced recurrent stroke and cardiovascular events in secondary prevention trials. Methods and results: Systematic search identified all randomized, controlled trials of medical secondary stroke prevention therapies published from 1960 to 2009. Randomized, controlled trials narrowly focused on single stroke mechanisms, including atrial fibrillation, cervical carotid stenosis, and intracranial stenosis, were excluded. From control arms of individual trials, we extracted data for baseline characteristics and annual event rates for recurrent stroke, fatal stroke, and major vascular events and analyzed trends over time. Fifty-nine randomized controlled trials were identified, enrolling 66 157 patients in control arms. Over the 5 decade periods, annual event rates declined, per decade, for recurrent stroke by 0.996% (P=0.001), fatal stroke by 0.282% (P=0.003), and major vascular events by 1.331% (P=0.001). Multiple regression analyses identified increasing antithrombotic use and lower blood pressures as major contributors to the decline in recurrent stroke. For recurrent stroke, annual rates fell from 8.71% in trials launched in the 1960s to 6.10% in the 1970s, 5.41% in the 1980s, 4.04% in the 1990s, and 4.98% in the 2000s. The sample size required for a trial to have adequate power to detect a 20% reduction in recurrent stroke increased 2.2-fold during this period. Conclusions: Recurrent stroke and vascular event rates have declined substantially over the last 5 decades, with improved blood pressure control and more frequent use of antiplatelet therapy as the leading causes. Considerably larger sample sizes are now needed to demonstrate incremental improvements in medical secondary prevention.

KW - randomized controlled trial

KW - recurrent stroke

KW - secondary stroke prevention

KW - systematic review

KW - vascular event rate

UR - http://www.scopus.com/inward/record.url?scp=79957460416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957460416&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.109.934786

DO - 10.1161/CIRCULATIONAHA.109.934786

M3 - Article

C2 - 21536995

AN - SCOPUS:79957460416

VL - 123

SP - 2111

EP - 2119

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 19

ER -